E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
circadian sleep-wake disturbances associated with ocular disease. |
|
E.1.1.1 | Medical condition in easily understood language |
Disturbance in sleep pattern associated with an eye condition |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Physiological processes [G07] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10009191 |
E.1.2 | Term | Circadian rhythm sleep disorder |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10009191 |
E.1.2 | Term | Circadian rhythm sleep disorder |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to assess the capability of melatonin to improve sleep-wake patterns in participants with various ocular diseases as compared to a placebo. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of the study is to assess the effect of melatonin administration on mood as compared to a placebo. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Participants will be Male or Female aged 18 to 75.
Participants identified as having a sleep problem as determined from their participation in the “Effect of Ocular Diseases on Sleep and ‘Body-Clocks’ (Circadian Rhythms)” study (REC Reference: B 11/SC/0093). These participants must have had abnormally elevated PSQI , and consented to be contacted for potential involvement in future research.
Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception (oral, patch, injected or implanted hormonal contraception, vaginal contraceptive ring, intra-uterine device or surgical sterilization, in addition to condom plus spermicide; or total sexual abstinence) during the trial and for 3 months thereafter.
Participants are willing and able to give informed consent for participation in the trial. |
|
E.4 | Principal exclusion criteria |
The participants may not enter the trial if ANY of the following apply: Non English speakers
Currently taking medications which may affect sleep (i.e. sedatives, anti-histamines, antidepressants and hypnotics) unless anophthalmic.
Previously taken medications which may affect sleep (i.e. sedatives, anti-histamines, antidepressants and hypnotics) within the last 2 months unless anophthalmic.
Substance abuser
Expecting to undergo a procedure involving anaesthetics during the study period
Actively involved in night work during the study period
IQ<70 as evidenced by medical notes and/or the opinion of the investigator.
Pregnant or breast-feeding women
Unlikely to cooperate in the study
Unable to complete the protocol due to absences e.g. holiday or participants who may have potential jet lag.
Significant urinary incontinence requiring regular use of pads
History of liver or kidney disease
History of sleep apnoea
Hypersensitivity to bio-melatonin active substance or excipients |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Comparison of sleep-wake patterns between groups using: 1. Pittsburgh Sleep Quality Index (PSQI) 2. Jupiter Sleep Questionnaire 3. General Health Questionnaire 4. SF-36 Questionnaire 5.Morningness-Eveningness (LARK/OWL) Questionnaire 6.Pictoral Epworth Sleepiness Scale 48 hour urine collection Sleep diary and actigraphy data
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Comparison of mood between groups as evidenced by Hospital Anxiety and Depression Scale (HADS) questionnaire |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The last phone call of the last patient. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 9 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 1 |